Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations

Abstract

1. SB-265123 is a novel αvβ3 (the vitronectin receptor) antagonist. Previous rat studies with it revealed an apparent absolute oral bioavailability (F_app) of greater than 100%. The present studies were conducted to investigate the potential causes for this observation.

2. Of 49 SB-265123 analogues evaluated in rat using an identical experimental design, F_app>100% was observed for 22 of them, suggesting that the observed F_app>100% with SB-265123 was not anomalous. All 22 compounds had clearances<15 ml min⁻¹ kg⁻¹. However, F_app>100% were not recorded for all low-clearance analogues.

3. Using SB-265123 as a model to investigate potential artefacts, it was demonstrated that using a chiral assay did not decrease F_app. Additionally, qualitative sample analysis demonstrated that no metabolites were present in the plasma that could interfere with the liquid chromatography coupled with tandem mass spectrometry detection assay. The high F_app was also dose-order-, delivery system- and vehicle-independent, and was not affected by the feeding status of the animals. Furthermore, a linearity experiment and an absorption study indicated that oral administration of SB-265123 does not result in hepatic portal vein concentrations that exceed the pharmacokinetic linearity of SB-265123.

4. These observations suggest that the observed F_app>100% for SB-265123 is not due to an experimental artefact or an obvious pharmacokinetic non-linearity. The mechanism(s) for this phenomenon is explored further in the second part of the present paper.